Ensysce Biosciences, Inc. 8-K

What Happened

• Ensysce Biosciences, Inc. announced its financial results for the fiscal quarter ended March 31, 2026 via a press release dated May 15, 2026. The company filed a Current Report on Form 8-K (dated May 15, 2026) reporting these results under Item 2.02 (Results of Operations and Financial Condition).
• The press release containing the announced results is included as Exhibit 99.1 to the Form 8-K.

Key Details

• 8-K filing date: May 15, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Reporting period: fiscal quarter ended March 31, 2026.
• Press release: included as Exhibit 99.1 to the Form 8-K (dated May 15, 2026).
• The filing also includes the Inline XBRL cover page (Exhibit 104).

Why It Matters

• The company has publicly released its latest quarterly results; investors should read the press release (Exhibit 99.1) to see key figures such as revenue, net income/loss, cash balance, and any management commentary or guidance.
• This 8-K confirms official disclosure of the quarter’s results but does not itself contain the detailed financial line items; for full audited or reviewed financial statements and notes, check the company’s subsequent periodic filings (e.g., 10-Q) and investor materials.